Healthcare
from24/7 Wall St.
4 days agoBarclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang - Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
Barclays raised Hims price target to $29 after Novo Nordisk deal removed legal risk, while Canaccord cut Progyny target to $19 citing uncertain 2026 outlook.